Herpes infections in breast cancer patients treated with adjuvant chemotherapy

Giovanna Masci, Massimo Magagnoli, Giuseppe Gullo, Emanuela Morenghi, Isabella Garassino, Matteo Simonelli, Armando Santoro

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: There is little information on Herpes zoster infection in breast cancer patients as a complication during adjuvant chemotherapy. The aim of this study is to evaluate the incidence of Herpes zoster and simplex infections in this patients setting. Methods: We analyzed 623 early-stage breast cancer patients in our Institute over a period of 7 years (1998-2005). Four-hundred and sixty-onepatients were treated with anthracycline-based chemotherapy, 116 with CMF and 46 with taxane-containing regimens. Results: Twelve (1.9%) developed herpes zoster; 9 patients, receiving anthracycline-based chemotherapy, two taxane-containing regimens, and one CMF regimen. Herpes zoster infection required treatment delay in 6 patients. Adjuvant chemotherapy was delayed for 1 week in 2 patients, while in 4 patients with more severe symptoms chemotherapy was delayed for 2 weeks. One patient, despite i.v. acyclovir, had severe postherpetic motor neuropathy with a permanent ambulation impairment, and chemotherapy was stopped. In our study, herpes zoster occurred in 55/1,000 cases/year. The reported incidence in the general population varies between 2.2 and 4.1 per 1,000 patients/year; therefore, the risk of developing herpes zoster in these patients may be 13- to 25-fold higher compared to the incidence in the general population. In addition, 13 of 623 patients developed herpes simplex. Conclusion: Our findings suggest that adjuvant chemotherapy can facilitate reactivation of herpes infection.

Original languageEnglish
Pages (from-to)164-167
Number of pages4
JournalOncology
Volume71
Issue number3-4
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Adjuvant Chemotherapy
Breast Neoplasms
Herpes Zoster
Infection
Drug Therapy
Herpes Simplex
Anthracyclines
Incidence
Acyclovir
Population
Walking

Keywords

  • Adjuvant chemotherapy
  • Breast cancer
  • Herpes infection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Herpes infections in breast cancer patients treated with adjuvant chemotherapy. / Masci, Giovanna; Magagnoli, Massimo; Gullo, Giuseppe; Morenghi, Emanuela; Garassino, Isabella; Simonelli, Matteo; Santoro, Armando.

In: Oncology, Vol. 71, No. 3-4, 08.2007, p. 164-167.

Research output: Contribution to journalArticle

Masci, Giovanna ; Magagnoli, Massimo ; Gullo, Giuseppe ; Morenghi, Emanuela ; Garassino, Isabella ; Simonelli, Matteo ; Santoro, Armando. / Herpes infections in breast cancer patients treated with adjuvant chemotherapy. In: Oncology. 2007 ; Vol. 71, No. 3-4. pp. 164-167.
@article{e4ffde14373041a393f47cfc8cfb5ba8,
title = "Herpes infections in breast cancer patients treated with adjuvant chemotherapy",
abstract = "Objective: There is little information on Herpes zoster infection in breast cancer patients as a complication during adjuvant chemotherapy. The aim of this study is to evaluate the incidence of Herpes zoster and simplex infections in this patients setting. Methods: We analyzed 623 early-stage breast cancer patients in our Institute over a period of 7 years (1998-2005). Four-hundred and sixty-onepatients were treated with anthracycline-based chemotherapy, 116 with CMF and 46 with taxane-containing regimens. Results: Twelve (1.9{\%}) developed herpes zoster; 9 patients, receiving anthracycline-based chemotherapy, two taxane-containing regimens, and one CMF regimen. Herpes zoster infection required treatment delay in 6 patients. Adjuvant chemotherapy was delayed for 1 week in 2 patients, while in 4 patients with more severe symptoms chemotherapy was delayed for 2 weeks. One patient, despite i.v. acyclovir, had severe postherpetic motor neuropathy with a permanent ambulation impairment, and chemotherapy was stopped. In our study, herpes zoster occurred in 55/1,000 cases/year. The reported incidence in the general population varies between 2.2 and 4.1 per 1,000 patients/year; therefore, the risk of developing herpes zoster in these patients may be 13- to 25-fold higher compared to the incidence in the general population. In addition, 13 of 623 patients developed herpes simplex. Conclusion: Our findings suggest that adjuvant chemotherapy can facilitate reactivation of herpes infection.",
keywords = "Adjuvant chemotherapy, Breast cancer, Herpes infection",
author = "Giovanna Masci and Massimo Magagnoli and Giuseppe Gullo and Emanuela Morenghi and Isabella Garassino and Matteo Simonelli and Armando Santoro",
year = "2007",
month = "8",
doi = "10.1159/000106065",
language = "English",
volume = "71",
pages = "164--167",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3-4",

}

TY - JOUR

T1 - Herpes infections in breast cancer patients treated with adjuvant chemotherapy

AU - Masci, Giovanna

AU - Magagnoli, Massimo

AU - Gullo, Giuseppe

AU - Morenghi, Emanuela

AU - Garassino, Isabella

AU - Simonelli, Matteo

AU - Santoro, Armando

PY - 2007/8

Y1 - 2007/8

N2 - Objective: There is little information on Herpes zoster infection in breast cancer patients as a complication during adjuvant chemotherapy. The aim of this study is to evaluate the incidence of Herpes zoster and simplex infections in this patients setting. Methods: We analyzed 623 early-stage breast cancer patients in our Institute over a period of 7 years (1998-2005). Four-hundred and sixty-onepatients were treated with anthracycline-based chemotherapy, 116 with CMF and 46 with taxane-containing regimens. Results: Twelve (1.9%) developed herpes zoster; 9 patients, receiving anthracycline-based chemotherapy, two taxane-containing regimens, and one CMF regimen. Herpes zoster infection required treatment delay in 6 patients. Adjuvant chemotherapy was delayed for 1 week in 2 patients, while in 4 patients with more severe symptoms chemotherapy was delayed for 2 weeks. One patient, despite i.v. acyclovir, had severe postherpetic motor neuropathy with a permanent ambulation impairment, and chemotherapy was stopped. In our study, herpes zoster occurred in 55/1,000 cases/year. The reported incidence in the general population varies between 2.2 and 4.1 per 1,000 patients/year; therefore, the risk of developing herpes zoster in these patients may be 13- to 25-fold higher compared to the incidence in the general population. In addition, 13 of 623 patients developed herpes simplex. Conclusion: Our findings suggest that adjuvant chemotherapy can facilitate reactivation of herpes infection.

AB - Objective: There is little information on Herpes zoster infection in breast cancer patients as a complication during adjuvant chemotherapy. The aim of this study is to evaluate the incidence of Herpes zoster and simplex infections in this patients setting. Methods: We analyzed 623 early-stage breast cancer patients in our Institute over a period of 7 years (1998-2005). Four-hundred and sixty-onepatients were treated with anthracycline-based chemotherapy, 116 with CMF and 46 with taxane-containing regimens. Results: Twelve (1.9%) developed herpes zoster; 9 patients, receiving anthracycline-based chemotherapy, two taxane-containing regimens, and one CMF regimen. Herpes zoster infection required treatment delay in 6 patients. Adjuvant chemotherapy was delayed for 1 week in 2 patients, while in 4 patients with more severe symptoms chemotherapy was delayed for 2 weeks. One patient, despite i.v. acyclovir, had severe postherpetic motor neuropathy with a permanent ambulation impairment, and chemotherapy was stopped. In our study, herpes zoster occurred in 55/1,000 cases/year. The reported incidence in the general population varies between 2.2 and 4.1 per 1,000 patients/year; therefore, the risk of developing herpes zoster in these patients may be 13- to 25-fold higher compared to the incidence in the general population. In addition, 13 of 623 patients developed herpes simplex. Conclusion: Our findings suggest that adjuvant chemotherapy can facilitate reactivation of herpes infection.

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - Herpes infection

UR - http://www.scopus.com/inward/record.url?scp=34548069384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548069384&partnerID=8YFLogxK

U2 - 10.1159/000106065

DO - 10.1159/000106065

M3 - Article

VL - 71

SP - 164

EP - 167

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3-4

ER -